Cerenis Therapeutics Hldg S.A. Actions au Porteur EO -,05
- BID
1.84
- ASK
1.85
- 653 Units3,074 Units
- 07/21, 12:47:01 PM
Sector and Industry
Healthcare, Healthcare Services
Performance (1Y)
59.78%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.16 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| UnitedHealth Group Inc. | 254.66 Bil. | 396.73 Bil. | 24.94 | -19.75 % | 0.00 | - |
| Thermo Fisher Scientific Inc. | 185.62 Bil. | 39.50 Bil. | 32.67 | +1.45 % | 0.00 | - |
| Danaher Corp. | 137.79 Bil. | 21.78 Bil. | 45.36 | -11.47 % | 0.00 | - |
| McKesson Corporation | 90.13 Bil. | 348.09 Bil. | 22.55 | +33.83 % | 0.00 | - |
| HCA Healthcare Inc. | 89.28 Bil. | 67.01 Bil. | 16.48 | +12.93 % | 0.00 | - |
| Elevance Health Inc. | 65.88 Bil. | 176.51 Bil. | 13.91 | -9.22 % | 0.00 | - |
| The Cigna Group | 61.74 Bil. | 243.65 Bil. | 12.41 | +66.33 % | 0.00 | - |
| Cencora Inc. | 51.58 Bil. | 291.15 Bil. | 39.26 | +1.16 % | 0.00 | - |
| IDEXX Laboratories Inc. | 45.92 Bil. | 3.81 Bil. | 51.74 | +14.41 % | 0.00 | - |
| Zoetis Inc. | 45.52 Bil. | 8.39 Bil. | 20.89 | +3.10 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.844 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 12:34:04 PM | |
| DAILY VOLUME (UNITS) | 3,201 | |
| DAILY HIGH / LOW | 1.856 | 1.816 |
| PREV. DAY'S PRICE | 1.806 | (07/20) |
| CHANGE DAY BEFORE | +0.04 | 2.10 % |
| 52 WEEK HIGH / LOW | 5.0917 (10/28) | 1.1582 (07/18) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.12 | -0.13 | -0.16 | -0.46 | -0.29 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 5.32 | 5.56 | 31.32 | - | - |
PRICE - SALES RATIO | 8.15 | 8.81 | 32.56 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A14QR9 |
| ISIN | FR0012616852 |
| SYMBOL | 609 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | CERENIS THER.HLDG EO -,05 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Healthcare Services |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.75 % | -26.04 % | -50.82 % | -48.54 % | 59.78 % | 55.57 % | 106.18 % | -44.94 % |
| HIGH | 1.89 | 2.53 | 3.80 | 4.01 | 5.09 | 5.09 | 5.09 | 4.01 |
| LOW | 1.81 | 1.81 | 1.81 | 1.81 | 1.16 | 0.86 | 0.86 | 1.81 |
Dividende
pro Aktie
CERENIS THER.HLDG EO -,05 does not deliver dividend information
Company profile
ABIONYX Pharma SA engages in the discovery and development of novel therapies for patients without existing or effective treatments. It develops biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis, and other severe diseases. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.